NasdaqGM:LNTHMedical Equipment
Is FDA Approval Of TAUKLARIFY Alzheimer’s Tau PET Agent Altering The Investment Case For Lantheus (LNTH)?
In August 2026, Lantheus Holdings received U.S. FDA approval for TAUKLARIFY (florquinitau F 18, MK-6240), a PET brain imaging agent to help assess tau neurofibrillary tangle pathology in adults with cognitive impairment being evaluated for Alzheimer’s disease, supported by data from more than 500 subjects across multiple clinical trials.
This approval not only broadens Lantheus’s Alzheimer’s imaging portfolio but also reinforces its role as a key partner to pharmaceutical companies...